Genetic Diversity in the Major Capsid L1 Protein of HPV-16 and HPV-18 in the Netherlands

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Apr 13

PMID 27070907

Citations 13

Authors

Audrey J King

Jan A Sonsma

Henrike J Vriend

Marianne A B van der Sande

Mariet C Feltkamp

Hein J Boot

Marion P G Koopmans

Affiliations

Soon will be listed here.

Abstract

Objectives: Intratypic molecular variants of human papillomavirus (HPV) type-16 and -18 exist. In the Netherlands, a bivalent vaccine, composed of recombinant L1 proteins from HPV-16 and -18, is used to prevent cervical cancer since 2009. Long-term vaccination could lead to changes in HPV-16 and -18 virus population, thereby hampering vaccination strategies. We determined the genetic diversity of the L1 gene in HPV-16 and -18 viral strains circulating in the Netherlands at the start of vaccination in order to understand the baseline genetic diversity in the Dutch population.

Methods: DNA sequences of the L1 gene were determined in HPV-16 (n = 241) and HPV-18 (n = 108) positive anogenital samples collected in 2009 and 2011 among Dutch 16- to 24-year old female and male attendees of the sexually transmitted infection (STI) clinics. Phylogenetic analysis was performed and sequences were compared to reference sequences HPV-16 (AF536179) and HPV-18 (X05015) using BioNumerics 7.1.

Results: For HPV-16, ninety-five single nucleotide polymorphism (SNPs) were identified, twenty-seven (28%) were non-synonymous variations. For HPV-18, seventy-one SNPs were identified, twenty-nine (41%) were non-synonymous. The majority of the non-silent variations were located in sequences encoding alpha helix, beta sheet or surface loops, in particular in the immunodominant FG loop, and may influence the protein secondary structure and immune recognition.

Conclusions: This study provides unique pre-vaccination/baseline data on the genetic L1 diversity of HPV-16 and -18 viruses circulating in the Netherlands among adolescents and young adults.

Citing Articles

Comparative Molecular Docking of Apigenin and Luteolin versus Conventional Ligands for TP-53, pRb, APOBEC3H, and HPV-16 E6: Potential Clinical Applications in Preventing Gynecological Malignancies.

Dunjic M, Turini S, Nejkovic L, Sulovic N, Cvetkovic S, Dunjic M Curr Issues Mol Biol. 2024; 46(10):11136-11155.

PMID: 39451541 PMC: 11505693. DOI: 10.3390/cimb46100661.

Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas.

Tsakogiannis D, Nikolaidis M, Zagouri F, Zografos E, Kottaridi C, Kyriakopoulou Z Viruses. 2023; 15(1).

PMID: 36680181 PMC: 9867070. DOI: 10.3390/v15010141.

Genetic Variability in the E6, E7, and L1 Genes of Human Papillomavirus Types 16 and 18 among Women in Saudi Arabia.

Alsanea M, Alsaleh A, Obeid D, Alhadeq F, Alahideb B, Alhamlan F Viruses. 2023; 15(1).

PMID: 36680149 PMC: 9862970. DOI: 10.3390/v15010109.

Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation.

Kombe Kombe A, Li B, Zahid A, Mengist H, Bounda G, Zhou Y Front Public Health. 2021; 8:552028.

PMID: 33553082 PMC: 7855977. DOI: 10.3389/fpubh.2020.552028.

Evidence for Missing Positive Results for Human Papilloma Virus 45 (HPV-45) and HPV-59 with the SPF-DEIA-LiPA (Version 1) Platform Compared to Type-Specific Real-Time Quantitative PCR Assays and Impact on Vaccine Effectiveness Estimates.

van Eer K, Leussink S, Severs T, van Marm-Wattimena N, Woestenberg P, Bogaards J J Clin Microbiol. 2020; 58(11).

PMID: 32907991 PMC: 7587105. DOI: 10.1128/JCM.01626-20.

References

Stewart A, Eriksson A, Manos M, Munoz N, Bosch F, Peto J . Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol. 1996; 70(5):3127-36. PMC: 190175. DOI: 10.1128/JVI.70.5.3127-3136.1996. View

de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56. DOI: 10.1016/S1470-2045(10)70230-8. View

Yue Y, Yang H, Wu K, Yang L, Chen J, Huang X . Genetic variability in L1 and L2 genes of HPV-16 and HPV-58 in Southwest China. PLoS One. 2013; 8(1):e55204. PMC: 3555822. DOI: 10.1371/journal.pone.0055204. View

Schiffman M, Wentzensen N . From human papillomavirus to cervical cancer. Obstet Gynecol. 2010; 116(1):177-185. DOI: 10.1097/AOG.0b013e3181e4629f. View

Roden R, Armstrong A, Haderer P, Christensen N, Hubbert N, Lowy D . Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol. 1997; 71(8):6247-52. PMC: 191893. DOI: 10.1128/JVI.71.8.6247-6252.1997. View

Cornut G, Gagnon S, Hankins C, Money D, Pourreaux K, Franco E . Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33, and 35. J Med Virol. 2010; 82(7):1168-78. DOI: 10.1002/jmv.21777. View

Xi L, Kiviat N, Hildesheim A, Galloway D, Wheeler C, Ho J . Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst. 2006; 98(15):1045-52. DOI: 10.1093/jnci/djj297. View

Ho L, Chan S, Burk R, Das B, Fujinaga K, Icenogle J . The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol. 1993; 67(11):6413-23. PMC: 238076. DOI: 10.1128/JVI.67.11.6413-6423.1993. View

Pastrana D, Vass W, Lowy D, Schiller J . NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology. 2001; 279(1):361-9. DOI: 10.1006/viro.2000.0702. View

10.

Gagnon S, Hankins C, Money D, Pourreaux K, Franco E, Coutlee F . Polymorphism of the L1 capsid gene and persistence of human papillomavirus type 52 infection in women at high risk or infected by HIV. J Acquir Immune Defic Syndr. 2006; 44(1):61-5. DOI: 10.1097/01.qai.0000247226.45375.01. View

11.

Mollers M, Boot Hein J, Vriend Henrike J, King Audrey J, van den Broek Ingrid V, van Bergen Jan E . Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands. Vaccine. 2012; 31(2):394-401. DOI: 10.1016/j.vaccine.2012.10.087. View

12.

Frati E, Bianchi S, Colzani D, Zappa A, Orlando G, Tanzi E . Genetic variability in the major capsid L1 protein of human papillomavirus type 16 (HPV-16) and 18 (HPV-18). Infect Genet Evol. 2011; 11(8):2119-24. DOI: 10.1016/j.meegid.2011.06.014. View

13.

Chen Z, Schiffman M, Herrero R, DeSalle R, Anastos K, Segondy M . Evolution and taxonomic classification of alphapapillomavirus 7 complete genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70. PLoS One. 2013; 8(8):e72565. PMC: 3745470. DOI: 10.1371/journal.pone.0072565. View

14.

Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. DOI: 10.1056/NEJMoa021641. View

15.

Vriend H, Bogaards J, van der Klis F, Scherpenisse M, Boot H, King A . Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection. PLoS One. 2013; 8(4):e60696. PMC: 3634056. DOI: 10.1371/journal.pone.0060696. View

16.

Cornet I, Gheit T, Clifford G, Combes J, Dalstein V, Franceschi S . Human papillomavirus type 16 E6 variants in France and risk of viral persistence. Infect Agent Cancer. 2013; 8(1):4. PMC: 3562255. DOI: 10.1186/1750-9378-8-4. View

17.

Villa L, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T . Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol. 2000; 81(Pt 12):2959-2968. DOI: 10.1099/0022-1317-81-12-2959. View

18.

Christensen N, Dillner J, Eklund C, Carter J, Wipf G, Reed C . Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology. 1996; 223(1):174-84. DOI: 10.1006/viro.1996.0466. View

19.

Rector A, Lemey P, Tachezy R, Mostmans S, Ghim S, Van Doorslaer K . Ancient papillomavirus-host co-speciation in Felidae. Genome Biol. 2007; 8(4):R57. PMC: 1896010. DOI: 10.1186/gb-2007-8-4-r57. View

20.

Malagon T, Drolet M, Boily M, Franco E, Jit M, Brisson J . Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12(10):781-9. DOI: 10.1016/S1473-3099(12)70187-1. View